ArticleReproductive sciences (Thousand Oaks, Calif.)2025
Carvacrol Shows Potential as a Treatment for Endometriosis with Inflammatory Reaction and Antioxidant Properties, Demonstrated in both In Vivo and In Vitro Studies.
Article in Reproductive sciences (Thousand Oaks, Calif.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Cepharanthine Reduces Endometriosis Lesions and Alters Mitochondrial and Autophagy-Related Signals in Endometriotic Stromal Cells.Molecules (Basel, Switzerland) · 2026Article
- Hepatoprotective effects of carvacrol: molecular mechanisms and insights from pre-clinical Studies.Molecular biology reports · 2026Review
- Natural products modulate programmed cell death signaling mechanism for treating endometriosis: a review.Frontiers in pharmacology · 2026Review
- Dietary Carvacrol Attenuates Cyclophosphamide-Induced Neurotoxicity: Implications for Food-Derived Neuroprotection and Molecular Mechanisms.Food science & nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Carvacrol is a phenolic monoterpenoid found in essential oils of oregano, thyme, and other plants. It possesses pharmacological activities, including antioxidant, anticancer, and anti-inflammatory properties, against several diseases. However, research on the treatment effect of endometriosis has not yet been conducted. Endometriosis is a condition characterized by tissues resembling the endometrium beyond the confines of the uterus, leading to intense pelvic pain and heightened risks of infertility. This study aimed to confirm the effectiveness of carvacrol as a treatment strategy for endometriosis with inflammatory regulation and antioxidant property. In the in vivo study, C57BL/6 J mice were orally administered 100 mg/kg carvacrol for 4 weeks and confirmed a decreased size of endometriosis lesions in the carvacrol-treated group, increased number of T cells in the spleen, and increased expression of cytokine-related genes in both tissues. Immortalized human ovarian endometriotic stromal cells (ihOESCs), derived from endometriotic lesions in patients, were used as an in vitro model for studying endometriosis pathophysiology. The findings of the in vitro study confirmed that carvacrol regulates calcium homeostasis, induces antioxidant effects, increases inflammatory response, deactivates the phosphatidylinositol 3-kinase (PI3K) signaling pathway, and ultimately induces autophagy. Therefore, we determined that carvacrol is suitable as an anti-inflammatory and anti-oxidant treatment strategy for endometriosis.
Indexed as
Identifiers
40274729What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.